Octreotide Efficacy and Safety in First-line Acromegalic Patients
NCT00171886
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Acromegaly
Interventions
DRUG:
Octreotide
Sponsor
Novartis Pharmaceuticals